S100P抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane 1-2: A431 cells, hela cells, Primary antibody: P08734(S100P Antibody) at dilution 1/650, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

The S100P antibody targets the S100 calcium-binding protein P (S100P), a member of the S100 protein family characterized by EF-hand calcium-binding domains. S100P is implicated in cellular processes such as proliferation, differentiation, and apoptosis, often dysregulated in cancer. Initially identified in placental tissue, S100P is overexpressed in various malignancies, including pancreatic, gastric, colorectal, and breast cancers, where it correlates with tumor progression, metastasis, and poor prognosis. Its interaction with the receptor for advanced glycation end products (RAGE) activates pro-survival signaling pathways like NF-κB and MAPK, promoting tumor cell survival and invasion.

S100P antibodies are widely used in research and diagnostics to detect S100P expression via techniques like immunohistochemistry (IHC), Western blotting, and immunofluorescence. These tools help elucidate S100P's role in tumor microenvironments, stromal interactions, and therapeutic resistance. Studies also explore its potential as a biomarker for early cancer detection or monitoring treatment response. Beyond oncology, S100P is studied in inflammatory and developmental contexts due to its regulatory functions in embryogenesis and tissue repair. Recent interest focuses on blocking S100P-RAGE signaling as a therapeutic strategy, with antibodies aiding in target validation and drug development. Despite progress, challenges remain in understanding tissue-specific regulation and clinical translation of S100P-targeted approaches.